Novartis closely monitors US reciprocal tariff policy amid global trade uncertainty

Novartis is closely monitoring the U.S. reciprocal tariff policy, which may impose 25% tariffs on pharmaceuticals. The company plans to expand in Japan with radiopharmaceutical production by 2026 and recently acquired Mariana Oncology for $1B to strengthen its oncology portfolio.

Swiss pharmaceutical giant Novartis is closely monitoring the potential impact of the United States’ proposed reciprocal tariff policy, which is expected to take shape in early April. Chief Executive Vas Narasimhan confirmed in Tokyo that the company is assessing the implications of the policy, particularly on pharmaceutical imports.  

U.S. President Donald Trump recently suggested imposing a 25% tariff on imported pharmaceuticals as part of broader trade measures targeting various industries, including semiconductors and automobiles. The move is part of efforts to restructure global trade dynamics and encourage domestic production.  

Meanwhile, Novartis is expanding its footprint in Japan, with plans to commence mass production of radiopharmaceuticals in 2026. These precision cancer treatments offer targeted therapy, a growing focus for the pharmaceutical industry.  

Last year, Novartis strengthened its oncology portfolio by acquiring U.S.-based Mariana Oncology for $1 billion upfront. This move enhances its offerings, which include prostate cancer treatment Pluvicto and Lutathera for rare gastrointestinal tumors.  

As global trade policies evolve, Novartis continues to navigate regulatory challenges while advancing its commitment to innovative cancer therapies.

Copied